90 related articles for article (PubMed ID: 8652251)
1. An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis.
Di Leo A; Bajetta E; Biganzoli L; Bohm S; Mariani L; Mènard S; Pilotti S; Fabbiani M; Gebbia V; Oriana S
Eur J Cancer; 1995 Dec; 31A(13-14):2248-54. PubMed ID: 8652251
[TBL] [Abstract][Full Text] [Related]
2. An intensive treatment with mitoxantrone and ifosfamide in second-line therapy of epithelial ovarian cancer.
Leo AD; Biganzoli L; Bohm S; Lupi G; Oriana S; Riboldi G; Spatti G; Vicario G; Di Re F; Bajetta E
Tumori; 1994 Dec; 80(6):443-7. PubMed ID: 7900234
[TBL] [Abstract][Full Text] [Related]
3. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
5. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
[TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
[TBL] [Abstract][Full Text] [Related]
7. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and tolerability of the combination of oxaliplatin, ifosfamide, and epirubicin in treatment of recurrent or platinum-resistant ovarian epithelial cancer patients].
Li XP; Cui H; Zhou JW; Wei LH; Wang JL; Zhao Y; Wang Y; Wang SJ; Zhu HL; Dong L; Zhang H
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):724-7. PubMed ID: 19087535
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study.
Lorusso V; Catino A; Leone B; Rabinovich M; Gargano G; Paradiso A; De Lena M
J Clin Oncol; 1993 Oct; 11(10):1952-6. PubMed ID: 8410121
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer.
Papadimitriou CA; Kouroussis C; Moulopoulos LA; Vlahos G; Rodolakis A; Kiamouris C; Diakomanolis E; Gika D; Michalas S; Dimopoulos MA
Cancer; 2001 Oct; 92(7):1856-63. PubMed ID: 11745258
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.
Song T; Kim MK; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Cancer Chemother Pharmacol; 2013 Sep; 72(3):653-60. PubMed ID: 23912693
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
Sørensen P; Pfeiffer P; Bertelsen K
Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. [The predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer].
Wei FH; Zhao XD; Zhang Y; He SR; Yang L
Zhonghua Yi Xue Za Zhi; 2007 May; 87(17):1187-9. PubMed ID: 17686239
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
González-Martín A; Crespo C; García-López JL; Pedraza M; Garrido P; Lastra E; Moyano A
Gynecol Oncol; 2002 Mar; 84(3):368-73. PubMed ID: 11855871
[TBL] [Abstract][Full Text] [Related]
17. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
Baur M; Fazeny-Doerner B; Hudec M; Sevelda P; Salzer H; Dittrich C
Cancer Invest; 2006 Feb; 24(1):22-7. PubMed ID: 16466988
[TBL] [Abstract][Full Text] [Related]
19. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
20. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
